Worth Charting

Health Care for more... that's our thinking here, 3 months later.

The <u>March 21st edition of **MONEY IN MOTION**</u>, which presented a case for being long Health Care, featured the following conclusion on page one:

"For those interested simply in expressing a pairs trade (long healthcare/short the market) we would buy the Health Care Select Sector SPDR (XLV) and sell the SPDR S&P 500 ETF (SPY)."

Since March 21st, the Sector has managed to outperform the market by 700 basis point (not exactly gangbusters, but outperformance nonetheless). And our thinking at present is that there's more outperformance ahead.

In terms of favorite names, we have examined the chart pattern of each of the 649 stocks in the Russell 3000 Index designated as 'Health Care' and would call your attention to the thirty (30) stocks below.

Trade well,

-Carter

Health Care Favorites:

Ticker	Company	Price	Sub Sector	Sector	Mkt Cap (billions)
AGL	agilon health inc	22	Medical/Nursing Services	Healthcare	8
ALKS	Alkermes Plc	29.88	Pharmaceuticals: Major	Healthcare	4
AXNX	Axonics, Inc.	57.78	Medical Specialties	Healthcare	2
BMY	Bristol-Myers Squibb Company	79.85	Pharmaceuticals	Health Care	170
CNC	Centene Corporation	84.5	Health Care Providers & Services	Health Care	49
CORT	Corcept Therapeutics Inc.	25.15	Pharmaceuticals	Health Care	2
CTLT	Catalent Inc	111.38	Pharmaceuticals	Health Care	19
CYTK	Cytokinetics, Incorporated	47.02	Biotechnology	Health Care	4
FOLD	Amicus Therapeutics, Inc.	10.86	Pharmaceuticals: Major	Healthcare	3
GBT	Global Blood Therapeutics Inc	30.1	Phamaceuticals: Major	Healthcare	2
HAE	Haemonetics Corporation	64.33	Health Care Equipment & Supplies	Health Care	3
HALO	Halozyme Therapeutics, Inc.	46.97	Biotechnology	Health Care	6
HQY	HealthEquity Inc	67.06	Health Care Providers & Services	Health Care	5
HUM	Humana Inc.	464.16	Health Care Providers & Services	Health Care	58
INCY	Incyte Corporation	77.81	Biotechnology	Health Care	17
IONS	Ionis Pharmaceuticals, Inc.	39.08	Phamaceuticals: Major	Healthcare	5
ITCI	Intra-Cellular Therapies, Inc.	58.57	Phamaceuticals: Major	Healthcare	5
JAZZ	Jazz Pharmaceuticals	156.95	Pharmaceuticals	Health Care	9
LLY	Eli Lilly and Company	329.1	Pharmaceuticals	Health Care	312
MRK	Merck & Co., Inc.	94.96	Pharmaceuticals	Health Care	240
NBIX	Neurocrine Biosciences, Inc.	99.32	Biotechnology	Health Care	9
NTRA	Natera, Inc.	39.96	Medical/Nursing Services	Healthcare	3
OPCH	Option Care Health Inc	28.69	Health Care Providers & Services	Health Care	5
PBH	Prestige Consumer Healthcare Inc	58.76	Pharmaceuticals	Health Care	3
PRGO	Perrigo Co. Plc	41.99	Pharmaceuticals	Health Care	5
PRVA	Privia Health Group, Inc.	29.34	Medical/Nursing Services	Healthcare	3
RPRX	Royalty Pharma Plc Class A	43.1	Pharmaceuticals: Major	Healthcare	26
STAA	STAAR Surgical Company	75.56	Health Care Equipment & Supplies	Health Care	3
SWAV	Shockwave Medical, Inc.	198.08	Health Care Equipment & Supplies	Health Care	7
VRTX	Vertex Pharmaceuticals Inc.	289.55	Biotechnology	Health Care	73

Worth Charting

info@worthcharting.com

1. Service a. Worth Charting is a technical research company conducting research and analyses on financial instruments. Worth Charting shares the results of its research to subscribers via a subscription-based service, but Worth Charting is not providing you any financial advice. Worth Charting and Services, including any facts, views opinions, recommendations, trades, trading strategies or systems, or descriptions of or references to products or securities, made available by Worth Charting is: i. for educational purposes only; and ii. not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, or sponsorship of any entity or security by Worth Charting. For all these reasons and others, your use of the information provided on this Website, or any Services, should be based upon your own due diligence and judgment of how best to use the information, and subsequently independently verified by a licensed broker, investment advisor, or financial planner. 2. Disclaimers Concerning The Service We Provide a. We are not an investment advisor. We do not provide personalized or individualized investment advice. Any information provided as part of the Services is impersonal and not specific to any person's investment needs. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult a registered investment advisor, attorney, or tax professional regarding your particular financial situation, investing strategies, or specific legal or tax situation. b. By reading the following, you acknowledge and agree that no content published or otherwise provided as part of any service constitutes a personalized recommendation or advice regarding the suitability of, or advisability of investing in, purchasing or selling any particular investment, security, portfolio, commodity, transaction or investment strategy. c. To the extent that any of the content may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. None of Worth Charting's editorial staff, employees, independent contractors, or owners (collectively, "Our Representatives") shall be liable for any investment decisions based upon or results obtained from the content. Trading in investments involves risk and volatility, and any of the investments discussed may lose their value after purchase. Past investment results are not necessarily indicative of future performance. Moreover, the information, research, and opinions that Worth Charting provides are obtained or derived from sources believed to be reliable, but we cannot guarantee their accuracy and completeness nor the opinions based thereon. d. You should not rely solely upon such information, research and opinions for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence and to seek the advice of a qualified investment professional before you make any investment. e. None of the information provided constitutes, or is intended to constitute, a recommendation by us of any particular security or other investment or trading strategy or a determination by us that any security or other investment or trading strategy is suitable for any specific person. Investing in securities or other investments, including those chosen in any of our products or in any of our content, is speculative in nature and involves substantial risk of loss of the money invested, f. We reserve the right to change, modify or discontinue any Content or any portion or feature of the Services. Such changes may include, but are not limited to, adding or removing particular outside contributors, experts or representatives, ceasing to provide access to a Service (and/or providing an alternative Service to you as a replacement), or changing the terms of engagement for a Service. We may make these changes or modifications at our sole discretion, either temporarily or permanently, at any time or from time to time, with or without notice to you. You agree that the Worth Charting shall not be liable to you or any third party for any such change or modification of the Content and/or Services and that your continued use of the changed or modified Content and/or Services, and/or continued access to the changed or modified Content and/or Services, constitutes your acceptance of any such